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The impact of personalised therapies
on respiratory medicine
J. Stuart Elborn
ABSTRACT: Stratified approaches to treating disease are very attractive, as efficacy is maximised
by identifying responders using a companion diagnostic or by careful phenotyping. This approach
will spare non-responders form potential side-effects. This has been pioneered in oncology where
single genes or gene signatures indicate tumours that will respond to specific chemotherapies.
Stratified approaches to the treatment of asthma with biological therapies are currently being
extensively studied. In cystic fibrosis (CF), therapies have been developed that are targeted at
specific functional classes of mutations. Ivacaftor, the first of such therapies, potentiates
dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein Class III
mutations and is now available in the USA and some European countries. Pivotal studies in patients
with a G551D mutation, the most common Class III mutation, have demonstrated significant
improvements in clinically important outcomes such as spirometry and exacerbations. Sweat
chloride was significantly reduced demonstrating a functional effect on the dysfunctional CFTR
protein produced by the G551D mutation. Symptom scores are also greatly improved to a level that
indicates that this is a transformational treatment for many patients. This stratified approach to the
development of therapies based on the functional class of themutations in CF is likely to lead to new
drugs or combinations that will correct the basic defect in many patients with CF.
KEYWORDS: Cystic fibrosis, personalised medicine, potentiator therapy
T
reatment approaches for respiratory dis-
eases have generally involved all patients
with a given condition receiving the same
therapy. This assumes that the underlying dis-
ease pathophysiology is similar for all patients
and that all patients will have the same treatment
response to a therapy. As this is invariably not
the case, there are increased efforts to develop
personalised therapies. The series of articles in
the current issue of the European Respiratory
Review has explored this approach in some detail,
describing its application to respiratory diseases,
in general, and cystic fibrosis, in particular [1–4].
Early examples of personalised or stratified
medicine mostly stem from the field of oncology
[2]. An archetypal example is trastuzumab, better
known as Herceptin1, for adjunctive treatment of
patients with human epidermal growth factor
receptor 2 (HER2) gene-amplified breast cancer
[5]. Two clinical trials have shown that trastuzu-
mab was associated with a 33% reduction in the
risk of death (p50.015) [6] and improved 3-yr
recurrence-free survival [7], compared to patients
who did not receive therapy. In the field of
endocrinology, PEARSON et al. [8] reported that
diabetic patients with mutations in the gene
encoding a subunit of the pancreatic ATP-sensi-
tive channel responded better to sulfonylurea
therapy treatment than insulin.
Examples of personalised medicine in the field of
respiratory medicine are also mostly in the area of
oncology, where knowledge of tumour-related
mutations has been used to refine the selection of
chemotherapy. The kinase inhibitor crizotinib was
specifically developed to treat nonsmall cell lung
cancer (NSCLC) patients who have a chromosomal
transformation that activates the anaplastic lym-
phoma kinase (ALK) gene [9]. Updated results of a
phase I trial assessing crizotinib in ALK-positive
NSCLC patients showed that 87 (60.8%) out of 143
patients had an objective response (95% CI 52.3–68.9%)
and median progression-free survival was 9.7 months
(95% CI 7.7–12.8 months) [10].
Extending these approaches to non-malignant
respiratory disease presents exciting possibilities,
and has already led to new approaches to pheno-
typing in areas such as chronic obstructive
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pulmonary disease, asthma, lung fibrosis or cancer using, for
example, serum markers, blood count, clinical phenotypes,
somatic genotype, germinal genotype and co-morbidities. Not
all of these approaches will necessarily end up being applicable
in practice, but they are worthy of investigation. Multiple
genome-wide association studies (GWAS) have been published
in respiratory medicine, mostly relating to genes associated with
asthma development or susceptibility to chronic obstructive
pulmonary disease [11]. Recently, there has been increased
interest in the role of interleukin (IL)-33 in asthma. IL-33 is
associated with promoting a type-1 T-helper cell response and
may play a role in chronic inflammation and airway remodelling
[12]. Moreover, IL-33 gene polymorphisms have been identified
in various asthma GWAS analyses [2, 13, 14].
The recent identification of the ability of ivacaftor, a cystic
fibrosis transmembrane conductance regulator (CFTR) mod-
ulator, to treat some patients with cystic fibrosis (CF) is the first
example in which a stratified medicine approach has resulted
in a major change in therapy for patients with this disease who
carry the gating channel mutation, G551D [15].
CFTR MODULATORS: A POTENTIAL PARADIGM FOR
‘‘PERSONALISED RESPIRATORY MEDICINE’’
Ivacaftor, formerly known as VX-770, was identified from a
library of 228,000 diverse drugs using high-throughput screen-
ing [13]. The candidate agent was subsequently shown to
increase the channel opening probability of G551D CFTR by
approximately six-fold and to partially restore fluid regulation
and cilia beating in cultured CF human bronchial epithelia with
the G551D/F508del genotype [3, 16]. These results provided
convincing evidence and rapidly advanced into clinical trials.
The efficacy and safety of ivacaftor was evaluated in two 48-
week, randomised, double-blind, placebo-controlled trials in
patients aged 6–11 yrs (ENVISION study) and patients aged
o12 yrs (STRIVE study) who have at least one copy of the
G551D-CFTR mutation [4].
Ivacaftor was shown to result in a rapid and sustained
improvement in lung function through to week 24 and this effect
continued through to week 48. Sweat chloride concentration
significantly decreased in both trials to levels below the diagnostic
cut-off point for CF. Moreover, treated patients in the ENVISION
and STRIVE studies demonstrated significant improvements in
body weight. The most common reported adverse events were
abdominal pain, diarrhoea, dizziness, rash, upper respiratory tract
reactions, headache and bacteria in sputum.
A separate phase II trial, DISCOVER, assessed the efficacy of
ivacaftor in patients homozygous for the F508del-CFTR mutation
[17]. No observed clinical effect was measured between the
treatment and placebo arms, suggesting that CFTR potentiation
with ivacaftor alone will not benefit CF patients who are
homozygous for F508del-CFTR. The reason for this is clear; ivacaftor
is a CFTR potentiator that targets gating defects in G551D-CFTR
channels. F508del mutation defects, however, can only be repaired
through use of a CFTR corrector, such as VX-808 [3].
Emerging CFTR modulators
Ivacaftor, the first CFTR modulator to be approved for clinical
use, can be only prescribed to approximately 4–5% of CF
patients who have the G551D mutation. If successful, other
emerging CFTR therapies will hold greater promise to treat
many more CF patients (table 1).
The read through agent, ataluren, is undergoing clinical trials
to treat CF in patients with mutations caused by premature
stop codons. Ataluren was linked to improvement in cough
over 3 months and increases in CFTR activity, as measured by
the nasal potential difference [18, 19]. Results of a phase III
pivotal trial are expected soon and are eagerly awaited.
VX-809 (or lumicaftor) is a CFTR corrector that has been
assessed in a phase IIa study of patients homozygous for the
F508del-CFTR mutation. The drug, which was well tolerated
with no significant safety signals, caused a moderate reduction
in sweat chloride compared to placebo [20]. Surprisingly, no
other clinically significant improvements were measured.
Nevertheless, the trial provided a basis for investigation into
the safety and efficacy of lumicaftor plus ivacaftor combination
therapy in CF patients homozygous or heterozygous for the
F508del-CFTR mutations [21].
Impact of personalised medicine on CF care
Based on experience with ivacaftor, the potential for CFTR
modulators (alone or combined) to transform the lives of a
significant number of CF patients is exciting. This optimism must
TABLE 1 Mechanism of action and targets of emerging cystic fibrosis transmembrane conductance regulator (CFTR) modulators
Mutation
class
Nature of defect Example mutations Pancreatic function# Modulator strategy Agents in development
I Biosynthesis G542X Insufficient Suppressor
Suppressor and potentiator"
Ataluren
II Trafficking F508del Insufficient Corrector
Corrector plus potentiator
VX-809 plus ivacaftor+
VX-661 plus ivacaftor+
III Channel gating G551D Insufficient Potentiator Ivacaftor (FDA approved, G551D)
Other gating mutations?"
IV Channel conductance R117H Sufficient Potentiator?" No clinical data available
V Low transcript levels 3849+10kb C-.T Sufficient Potentiator?" No clinical data available
FDA: US Food and Drug Administration. #: when in trans with a non-functional CFTR mutation; ": theoretical approach based on nature of defect and known drug
mechanism; +: currently in phase II trials. Reproduced from [15] with permission from the publisher.
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also be guarded: many trials of promising drug candidates are
still in their infancy and the long-term effect of these therapies is
still unknown. Nevertheless, as personalised therapies, CFTR
modulators truly represent a milestone in CF treatment.
CONCLUSION
The theoretical benefit of personalised respiratory medicine is
almost beyond reproof. However, despite an increasing number
of success stories, such as crizotinib, trastuzumab, imatinib and
ivacaftor, the development of personalised therapies remains a
significant challenge; one that is perhaps above and beyond
those typically faced by the pharmaceutical industry, which also
has to consider how to recoup the not-insignificant development
costs in a specialised and limited market. Overcoming these
challenges will involve input and consensus from funders,
scientists, providers, patients and regulatory authorities.
Nevertheless, personalised medicine has the genuine potential
to revolutionise healthcare as we know it.
STATEMENT OF INTEREST
J.S. Elborn has received fees for consultancy and speaking from Vertex.
He received payment as a grant for three clinical trials (J50,000).
REFERENCES
1 Elborn JS. Personalised medicine for cystic fibrosis: treating the
basic defect. Eur Respir Rev 2013; 22: 3–5.
2 Hall IP. Stratified medicine: drugs meet genetics. Eur Respir Rev
2013; 22: 53–57.
3 Derichs N. Targeting a genetic defect: cystic fibrosis transmem-
brane conductance regulator modulators modulators in cystic
fibrosis. Eur Respir Rev 2013; 22: 58–65.
4 Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic
fibrosis and the G551D-CFTR mutation. Eur Respir Rev 2013; 22:
66–71.
5 Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy
plus a monoclonal antibody against HER2 for metastatic breast
cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792.
6 Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer. N Engl J
Med 2005; 353: 1673–1684.
7 Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant
docetaxel or vinorelbine with or without trastuzumab for breast
cancer. N Engl J Med 2006; 354: 809–820.
8 Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin
to oral sulfonylureas in patients with diabetes due to Kir6.2
mutations. N Engl J Med 2006; 355: 467–477.
9 Ou SH, Bartlett CH, Mino-Kenudson M, et al. Crizotinib for the
treatment of ALK-rearranged non-small cell lung cancer: a success
story to usher in the second decade of molecular targeted therapy
in oncology. Oncologist 2012; 17: 1351–1375.
10 Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of
crizotinib in patients with ALK-positive non-small-cell lung
cancer: updated results from a phase 1 study. Lancet Oncol 2012;
13: 1011–1019.
11 Todd JL, Goldstein DB, Ge D, et al. The state of genome-wide
association studies in pulmonary disease: a new perspective. Am J
Respir Crit Care Med 2011; 184: 873–880.
12 Prefontaine D, Nadigel J, Chouiali F, et al. Increased IL-33
expression by epithelial cells in bronchial asthma. J Allergy Clin
Immunol 2010; 125: 752–754.
13 Smith DE. IL-33: a tissue derived cytokine pathway involved
in allergic inflammation and asthma. Clin Exp Allergy 2010; 40:
200–208.
14 Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st
century perspective. Immunol Rev 2011; 242: 10–30.
15 Clancy JP, Jain M. Personalized medicine in cystic fibrosis: dawning
of a new era. Am J Respir Crit Care Med 2012; 186: 593–597.
16 Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the
F508del-CFTR protein processing defect in vitro by the investiga-
tional drug VX-809. Proc Nat Acad Sci USA 2011; 108: 18843–18848.
17 Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with
cystic fibrosis who are homozygous for the F508del-CFTR
mutation. Chest 2012; 142: 718–724.
18 Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124
treatment of cystic fibrosis caused by nonsense mutations: a
prospective phase II trial. Lancet 2008; 372: 719–727.
19 Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124)
induces cystic fibrosis transmembrane conductance regulator
protein expression and activity in children with nonsense
mutation cystic fibrosis. Am J Respir Crit Care Med 2010; 182:
1262–1272.
20 Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study
of VX-809, an investigational CFTR corrector compound, in
subjects with cystic fibrosis homozygous for the F508del-CFTR
mutation. Thorax 2012; 67: 12–18.
21 Pettit RS. Cystic fibrosis transmembrane conductance regulator-
modifying medications: the future of cystic fibrosis treatment. Ann
Pharmacother 2012; 46: 1065–1075.
REVIEW: IMPACT OF PERSONALISED THERAPIES J.S. ELBORN
74 VOLUME 22 NUMBER 127 EUROPEAN RESPIRATORY REVIEW
